Cancer Harboring BRAF Alterations clinical trials at UCSF
1 research study open to eligible people
Some cancers have BRAF alterations, which are specific genetic changes affecting tumor growth. UCSF is investigating a medication called plixorafenib for its safety and effectiveness in treating such cancers. Trial participants are monitored to gather data on how this drug works for them.
FORE8394 in Participants With Cancer Harboring BRAF Alterations
open to eligible people ages 10 years and up
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
San Francisco, California and other locations
Last updated: